Approach
Our approach balances affinity and avidity to generate novel immunotherapies that will enable durable patient responses.
Empirical
We are intentional and unrelenting in our focus on rigorous science and verifiable observations.
Intentional
We select validated cancer targets and novel target combinations to build on existing knowledge in creating better molecules.
Best
Through rigorous science and full-on dedication, we are building best-in-class and first-in-class therapeutics.